Ferroptosis is cell death caused by damage to fatty molecules in cell membranes. Antibody-directed carriers are being studied to deliver drugs that trigger it in tumors.
A primary study linked an FGFR4 antibody to the ferroptosis inducer sulfasalazine through a cleavable linker and reported target-dependent activity in liver cancer models. A separate study used an anti-PD-L1 antibody linked to a nanogel encapsulating imidazole ketone erastin, or IKE, with ferroptosis and tumor suppression in experimental models. The former is a directly conjugated small-molecule payload; the latter is an antibody-directed nanocarrier. Both are preclinical evidence and should retain their different delivery formats.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/